NeoTract to Unveil New Clinical Data on the UroLift® System at American Urological Association 2018 Meeting
PLEASANTON, Calif.--(BUSINESS WIRE)--May 16, 2018--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced a series of presentations planned for the 113th Annual Meeting of the American Urological Association (AUA) taking place May 18 - 21 in San Francisco.
NeoTract will have a significant presence at AUA 2018. Most notably, results from the MedLift study, a study supporting the recently-added indication for treating enlarged prostates with an obstructive median lobe, will be presented as a late-breaking abstract on Sunday, May 20.
The MedLift Study is a multi-center prospective study of the minimally invasive UroLift ® System for the treatment of the median lobe in men with benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. Earlier this year, NeoTract announced that the U.S. Food and Drug Administration (FDA) cleared new indications for the UroLift System, making patients who have an obstructive median lobe and those as young as 45 eligible to receive treatment with the UroLift System for their BPH symptoms. With this expanded indication, 95% of men 45 years and older with BPH symptoms are now potential candidates for the UroLift System. Importantly the UroLift system is the only BPH procedure to show no new onset sustained ejaculatory or erectile dysfunction.
Other podium presentations will provide new insights on surgical techniques and predictors of patient response to the company’s UroLift System. Following is a detailed schedule of the company’s events in chronological order, all of which will take place at the Moscone Center in San Francisco (times are U.S. Pacific Daylight Time).Saturday, May 19, 3-4pm PST in the Esplanade Room: Prostatic Urethral Lift Video Presentation: Session: Plenary: Surgical Techniques: Tips & Tricks: Benign Prostatic Hyperplasia by Dr. Gregg Eure. Sunday, May 20, 1:30pm PST in MCC West, Room 3006: Predictors of Response to the Prostatic Urethral Lift Treatment: Session: Plenary: MP62 – BPH: Surgical Therapy & New Technology by Dr. Steven Kaplan et al. Sunday, May 20, 4-4:15pm PST in MCC North, Hall E: Multi-Center Prospective Study of the Obstructive Median Lobe: The MedLift Study, an Extension of the LIFT Randomized Study. Session: Plenary: Next Frontier (Late-Breaking Abstract) by Dr. Daniel Rukstalis et al.
Additionally, in-booth presentations given by experienced UroLift implanters will be held in booth 909 on Saturday and Sunday at 10:30am, 1:30pm, and 3pm PST, and on Monday at 10:30am PST.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. More than 50,000 men worldwide have been treated with the UroLift System. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.
MA00265-01 Rev A
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005334/en/
Jake Elguicze, 610-948-2836
Treasurer and Vice President, Investor Relations
Nicole Osmer, 650-454-0505
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH FDA SCIENCE
Copyright Business Wire 2018.
PUB: 05/16/2018 06:45 AM/DISC: 05/16/2018 06:45 AM